181 related articles for article (PubMed ID: 12115576)
1. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
2. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
3. TRA-1-60: a new serum marker in patients with germ-cell tumors.
Marrink J; Andrews PW; van Brummen PJ; de Jong HJ; Sleijfer DT; Schraffordt Koops H; Oosterhuis JW
Int J Cancer; 1991 Sep; 49(3):368-72. PubMed ID: 1717384
[TBL] [Abstract][Full Text] [Related]
4. Observations after orchiectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Kuo JY; Chin T; Hsieh YL; Lin AT; Chang YH; Wei C; Chen KK; Chang LS
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):356-61. PubMed ID: 10389293
[TBL] [Abstract][Full Text] [Related]
5. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
6. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
7. AFP and HCG in germ cell tumors.
Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
9. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
10. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
Toner GC
J Clin Oncol; 2004 Oct; 22(19):3842-5. PubMed ID: 15302908
[No Abstract] [Full Text] [Related]
11. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
12. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
[TBL] [Abstract][Full Text] [Related]
13. Lectin-reactive alpha-fetoprotein as a marker for testicular tumor activity.
Kawai K; Kojima T; Miyanaga N; Hattori K; Hinotsu S; Shimazui T; Akaza H
Int J Urol; 2005 Mar; 12(3):284-9. PubMed ID: 15828957
[TBL] [Abstract][Full Text] [Related]
14. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases.
Ushio Y; Kochi M; Kuratsu J; Itoyama Y; Marubayashi T
J Neurosurg; 1999 Jan; 90(1):133-7. PubMed ID: 10413166
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
16. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.
Davis BE; Herr HW; Fair WR; Bosl GJ
J Urol; 1994 Jul; 152(1):111-3; discussion 114. PubMed ID: 7515445
[TBL] [Abstract][Full Text] [Related]
17. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.
Eastham JA; Wilson TG; Russell C; Ahlering TE; Skinner DG
Urology; 1994 Jan; 43(1):74-80. PubMed ID: 7506856
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors.
Inanç SE; Meral R; Darendeliler E; Yasasever V; Onat H
Acta Oncol; 1999; 38(4):505-9. PubMed ID: 10418719
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
